Physician profile
Michael H Theodoulou
NPI 1760430755
$209,905.93
in general payments reported to CMS, 2019-2025
36 companies · $57K in 2025
The $57K reported for 2025 was more than what 99% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $2,413 · 2021: $17K · 2022: $43K · 2023: $50K · 2024: $21K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $107K · Travel and Lodging: $18K · Food and Beverage: $3,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $107,182.50 |
| Travel and Lodging | $17,723.10 |
| Food and Beverage | $3,461.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $107,395.62 | 2019-2025 | |
| Integra Lifesciences Corporation | $56,871.72 | 2019-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Avitus Orthopaedics, INC. | $14,675.00 | 2021-2023 | |
| Arthrex, INC. | $14,182.10 | 2019-2020 | |
| Kairos Surgical INC | $6,248.00 | 2019-2024 | |
| Wishbone Medical INC. | $4,012.71 | 2021-2022 | |
| Orthofix Medical, INC. | $2,078.00 | 2019-2023 | Physio-Stim |
| Arteriocyte Medical Systems, INC. | $1,226.16 | 2021 | |
| Kerecis Limited | $480.01 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Stryker Corporation | $321.57 | 2019-2022 | |
| Misonix INC | $275.02 | 2021 | |
| Smith+Nephew, INC. | $216.98 | 2019-2022 | |
| My01 INC. | $181.23 | 2023 | My01 Continuous Compartmental Pressure Monitor |
| Bonalive INC | $166.82 | 2025 | |
| Avita Medical Americas, LLC | $145.41 | 2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wright Medical Technology, INC. | $142.89 | 2019 | |
| Sanara Medtech INC. | $140.27 | 2021 | |
| Bone Support INC. | $130.47 | 2021-2022 | |
| Biocomposites INC | $122.22 | 2023 | Stimulan |
| Organogenesis INC. | $119.14 | 2019 | |
| Averitas Pharma INC. | $116.37 | 2024 | Qutenza |
| Linvatec Corporation | $107.89 | 2025 | Colink Sfx |
| Convatec INC. | $89.49 | 2023 | |
| Nevro Corp. | $65.68 | 2024 | Senza |
| Zimmer Biomet Holdings, INC. | $59.88 | 2023-2024 | Cannulated Screws, Avitus Bone Harvester |
| Solventum Corporation | $59.75 | 2025 | Activ.A.C. |
| Bioventus LLC | $41.28 | 2021-2022 | |
| Derma Sciences, INC. | $39.80 | 2019 | |
| In2bones USA, LLC | $38.48 | 2020 | |
| Life Spine, INC. | $34.31 | 2022 | |
| Medartis INC. | $28.53 | 2019 | |
| Axogen | $27.24 | 2022 | |
| Medshape, INC. | $22.15 | 2023 | Dynaclip Bone Fixation System, Quattro, 22mm X 20mm X 20mm |
| Vertex Pharmaceuticals Incorporated | $19.63 | 2025 | |
| Myriad Genetic Laboratories, INC. | $17.56 | 2022 | |
| Checkpoint Surgical, INC | $6.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Theodoulou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.